

**SUNOSI
(solriamfetol)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Excessive daytime sleepiness due to narcolepsy
 - a. Inadequate treatment response, intolerance, or contraindication to **ONE** of the following:
 - i. Provigil (modafinil) or Nuvigil (armodafinil)
 - ii. Stimulant, such as amphetamine, methylphenidate, or dexamethylphenidate
2. Excessive daytime sleepiness due to obstructive sleep apnea (OSA)
 - a. Compliant with other standard OSA treatments (such as CPAP and oral appliances) for at least one month prior to initiating Sunosi
 - b. Treatment for underlying airway obstruction will be continued during treatment with Sunosi

AND ALL of the following for **ALL** indications:

- a. **NO** concomitant use of a MAOI (monoamine oxidase inhibitor) (must be >14 days post discontinuing therapy)
- b. Prescriber agrees to monitor patient's blood pressure and heart rate
- c. **NO** end stage renal disease (ESRD)

Prior - Approval Limits

Quantity 90 tablets per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older



**BlueCross
BlueShield**

Federal Employee Program.

SUNOSI (solriamfetol)

Diagnoses

Patient must have **ONE** of the following:

1. Excessive daytime sleepiness due to narcolepsy
2. Excessive daytime sleepiness due to obstructive sleep apnea (OSA)
 - a. Compliant with other standard OSA treatments (such as CPAP and oral appliances)
 - b. Treatment for underlying airway obstruction will be continued during treatment with Sunosi

AND ALL of the following for **ALL** indications:

- a. **NO** concomitant use of a MAOI (monoamine oxidase inhibitor) (must be >14 days post discontinuing therapy)
- b. Prescriber agrees to monitor patient's blood pressure and heart rate
- c. **NO** end stage renal disease (ESRD)

Prior - Approval *Renewal* Limits

Same as above